Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2Phase NA 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Standard of Care 31Specimen Handling 27Interviews as Topic 24Educational Status 24Practice Guidelines as Topic 22Methods 22Early Intervention, Educational 22Exercise 19Blood Specimen Collection 16Surveys and Questionnaires 12Radiosurgery 11Magnetic Resonance Spectroscopy 11Patient Navigation 10Palliative Care 9Counseling 8Diet Therapy 7Surgical Procedures, Operative 6Resistance Training 6Health Promotion 6Radiotherapy 5Nutrition Assessment 5Magnetic Resonance Imaging 5Genetic Testing 5X-Rays 4Watchful Waiting 4Positron-Emission Tomography 4Neoadjuvant Therapy 4Human Papillomavirus DNA Tests 4Dietary Supplements 4Colposcopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Erlotinib Hydrochloride × 30 days × Clear all
NCT02194738 2026-05-29

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

National Cancer Institute (NCI)

Phase NA Active not recruiting
8,300 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡